PVR and metastatic melanoma: Almost 91.5% of all melanoma specimens (primary and metastatic melanomas) showed an enhanced NECL-5 immunoreactivity (Figure 3c and 3d) when compared with the benign nevi tissue samples (Figure 3b) (P<0.0001).